Leber congenital amaurosis (LCA) reports a sustained improvement for the treatment of a novel anti-oligonucleotide (AON) therapy.
A report published in Nature Medicine has shown that an RNA antisense oligonucleotide (AON) treatment, directed to the CEP290 gene for LCA10, found one patient… Read More »Leber congenital amaurosis (LCA) reports a sustained improvement for the treatment of a novel anti-oligonucleotide (AON) therapy.